Filing Details

Accession Number:
0001127602-11-016669
Form Type:
4
Zero Holdings:
No
Publication Time:
2011-05-17 18:04:04
Reporting Period:
2011-05-13
Filing Date:
2011-05-17
Accepted Time:
2011-05-17 18:04:04
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
874663 Alkermes Inc ALKS Pharmaceutical Preparations (2834) 232472830
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1235595 L Kathryn Biberstein 852 Winter St.
Waltham MA 02451
Svp, General Counsel No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2011-05-13 8,800 $7.69 41,232 No 4 M Direct
Common Stock Disposition 2011-05-13 8,800 $18.00 32,432 No 4 S Direct
Common Stock Acquisiton 2011-05-16 52,012 $7.69 84,444 No 4 M Direct
Common Stock Disposition 2011-05-16 52,012 $18.01 32,432 No 4 S Direct
Common Stock Acquisiton 2011-05-16 64,188 $7.69 96,620 No 4 M Direct
Common Stock Disposition 2011-05-16 64,188 $18.01 32,432 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Non Qualified Stock Option (Right to Buy) Disposition 2011-05-13 8,800 $0.00 8,800 $7.69
Common Stock Incentive Stock Option (Right to Buy) Disposition 2011-05-16 52,012 $0.00 52,012 $7.69
Common Stock Non Qualified Stock Option (Right to Buy) Disposition 2011-05-16 64,188 $0.00 64,188 $7.69
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
164,188 2004-02-03 2013-02-03 No 4 M Direct
0 2004-02-03 2013-02-03 No 4 M Direct
100,000 2004-02-03 2013-02-03 No 4 M Direct
Footnotes
  1. This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
  2. This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
  3. The range of sale prices was $18.00 to $18.02. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
  4. The range of sale prices was $18.00 to $18.07. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
  5. The option becomes exercisable in equal annual installments over a four year period, at the rate of 25% per year commencing one year after the grant date.